NCT06327698View on ClinicalTrials.gov

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions
Melanoma
Interventions
DRUG

Cadonilimab

Injectable solution

DRUG

anlotinib

capsule

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER